WO2014123543A3 - Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation - Google Patents

Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2014123543A3
WO2014123543A3 PCT/US2013/025543 US2013025543W WO2014123543A3 WO 2014123543 A3 WO2014123543 A3 WO 2014123543A3 US 2013025543 W US2013025543 W US 2013025543W WO 2014123543 A3 WO2014123543 A3 WO 2014123543A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
active agent
carrier
peptides
compositions
Prior art date
Application number
PCT/US2013/025543
Other languages
English (en)
Other versions
WO2014123543A2 (fr
Inventor
John A. MURASKI Jr.
Samir Mitragotri
Ming Chen
Original Assignee
Convoy Therapeutics
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convoy Therapeutics, The Regents Of The University Of California filed Critical Convoy Therapeutics
Priority to PCT/US2013/025543 priority Critical patent/WO2014123543A2/fr
Publication of WO2014123543A2 publication Critical patent/WO2014123543A2/fr
Publication of WO2014123543A3 publication Critical patent/WO2014123543A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions qui facilitent l'administration d'un agent actif ou d'un vecteur d'agent actif, les compositions étant capables de pénétrer dans la couche cornée (SC) et/ou dans les membranes cellulaires de cellules viables. Dans certains modes de réalisation, les compositions comprennent un peptide, un agent actif et un vecteur comprenant l'agent actif, le peptide ayant une séquence d'acides aminés énoncée dans l'un des numéros d'identifications de séquences : 1 à 18 ; le peptide est associé et/ou conjugué à l'agent actif, au vecteur ou aux deux ; le vecteur est choisi dans le groupe constitué d'une micelle, d'un liposome, d'un ethosome et de combinaisons de ceux-ci ; la composition est capable de pénétrer dans la couche cornée (SC) lorsqu'elle est mise en contact avec celle-ci ou de pénétrer dans une cellule lorsqu'elle est mise en contact avec celle-ci, éventuellement la composition comprenant en outre un ou plusieurs peptides libres ayant une séquence d'acides aminés énoncée dans l'un des numéros d'identifications de séquences : 1 à 18. L'invention concerne également des procédés d'administration d'agents actifs à des sujets, des méthodes de traitement de sujets souffrant d'affections dermatologiques et des méthodes d'atténuation de l'expression des ARNm des sujets qui en ont besoin et/ou de traitement de maladies et/ou de troubles.
PCT/US2013/025543 2013-02-11 2013-02-11 Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation WO2014123543A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2013/025543 WO2014123543A2 (fr) 2013-02-11 2013-02-11 Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/025543 WO2014123543A2 (fr) 2013-02-11 2013-02-11 Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
WO2014123543A2 WO2014123543A2 (fr) 2014-08-14
WO2014123543A3 true WO2014123543A3 (fr) 2015-06-11

Family

ID=51300232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/025543 WO2014123543A2 (fr) 2013-02-11 2013-02-11 Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2014123543A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3206148A1 (fr) 2021-01-24 2022-07-28 Michael David FORREST Modificateurs therapeutiques du mode inverse de l'atp-synthase
CN114107397A (zh) * 2021-11-19 2022-03-01 深圳市大鳄生物科技股份有限公司 递送带负电荷的核酸的递送系统、复合物及药物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20090298915A1 (en) * 2006-03-31 2009-12-03 Eugene Pius Joseph Healy Topical drug delivery
US20100209447A1 (en) * 2007-08-29 2010-08-19 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US20120100569A1 (en) * 2009-04-28 2012-04-26 Liu David R Supercharged proteins for cell penetration
US20120128756A1 (en) * 2010-11-09 2012-05-24 Tracy Hsu Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof
US20120251618A1 (en) * 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298915A1 (en) * 2006-03-31 2009-12-03 Eugene Pius Joseph Healy Topical drug delivery
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20100209447A1 (en) * 2007-08-29 2010-08-19 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US20120100569A1 (en) * 2009-04-28 2012-04-26 Liu David R Supercharged proteins for cell penetration
US20120128756A1 (en) * 2010-11-09 2012-05-24 Tracy Hsu Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof
US20120251618A1 (en) * 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVE ET AL.: "Ethosome: A Novel Approach of Transdermal Drug Delivery System.", INT. J. ADV. RES. PHARM. BIO. SCI., vol. 1, no. 4, 2012, pages 439 - 452 *

Also Published As

Publication number Publication date
WO2014123543A2 (fr) 2014-08-14

Similar Documents

Publication Publication Date Title
WO2012064429A3 (fr) Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
WO2016090287A3 (fr) Formulations de cannabinoïdes transdermiques
EP4349414A3 (fr) Méthodes et formulations pour l'administration transdermique
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
SG194155A1 (en) Multilayer thin film drug delivery device and methods of making and using the same
WO2013067271A3 (fr) Mousses aérosols dermatologiques stables utilisant des propulseurs réactifs
MX2015012433A (es) Matriz de microestructura para suministro de agentes activos.
MX347195B (es) Sistema de administración transdérmica de fármacos y método para usar el mismo.
WO2011026076A3 (fr) Compositions topiques contenant un stéroïde
WO2011156030A3 (fr) Compositions sous forme de mousse à base d'aérosol émollient riche en huile
BR112016021023A8 (pt) composições de corticosteroides tópicos
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
NZ703574A (en) A topical composition comprising a film-forming polymer for delivering an active ingredient to skin
WO2017091739A8 (fr) Pulvérisation filmogène topique
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
WO2016210376A3 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
WO2013090523A3 (fr) Procédés, systèmes et compositions pour l'administration de microarn issu de cellules/à base de vésicules
WO2015023649A3 (fr) Peptides destinés à améliorer l'administration transdermique
WO2018081726A3 (fr) Compositions pharmaceutiques et procédés d'utilisation pour l'activation de fibroblastes humains et d'apoptose de myofibroblastes
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
IL273329A (en) Modulation of hepatic-hepatic epidermal growth factor activity to heal the eardrum membrane
PH12018500910A1 (en) Novel method of use and compositions
WO2014123543A3 (fr) Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation
WO2015063613A3 (fr) Corps d'inclusion pour administration transdermique d'agents thérapeutiques et cosmétiques

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21/12/2016)

122 Ep: pct application non-entry in european phase

Ref document number: 13874526

Country of ref document: EP

Kind code of ref document: A2